114 related articles for article (PubMed ID: 9845029)
1. Use of transient evoked otoacoustic emissions to detect and monitor cochlear damage caused by platinum-containing drugs.
Yardley MP; Davies CM; Stevens JC
Br J Audiol; 1998 Oct; 32(5):305-16. PubMed ID: 9845029
[TBL] [Abstract][Full Text] [Related]
2. Evoked otoacoustic emissions--an approach for monitoring cisplatin induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Segas J; Tsakanikos M; Adamopoulos G
Int J Pediatr Otorhinolaryngol; 2001 May; 59(1):47-57. PubMed ID: 11376818
[TBL] [Abstract][Full Text] [Related]
3. Clinical monitoring using otoacoustic emissions.
Probst R; Harris FP; Hauser R
Br J Audiol; 1993 Apr; 27(2):85-90. PubMed ID: 8220286
[TBL] [Abstract][Full Text] [Related]
4. [Changes in transitory evoked otoacoustic emissions in chemotherapy with cisplatin and 5FU].
Beck A; Maurer J; Welkoborsky HJ; Mann W
HNO; 1992 Apr; 40(4):123-7. PubMed ID: 1601678
[TBL] [Abstract][Full Text] [Related]
5. Evoked otoacoustic emissions and pure tone threshold audiometry in patients receiving cisplatinum therapy.
Zorowka PG; Schmitt HJ; Gutjahr P
Int J Pediatr Otorhinolaryngol; 1993 Jan; 25(1-3):73-80. PubMed ID: 8436482
[TBL] [Abstract][Full Text] [Related]
6. Early changes in auditory function as a result of platinum chemotherapy: use of extended high-frequency audiometry and evoked distortion product otoacoustic emissions.
Knight KR; Kraemer DF; Winter C; Neuwelt EA
J Clin Oncol; 2007 Apr; 25(10):1190-5. PubMed ID: 17401008
[TBL] [Abstract][Full Text] [Related]
7. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
[TBL] [Abstract][Full Text] [Related]
8. Distortion product otoacoustic emissions: an objective technique for the screening of hearing loss in children treated with platin derivatives.
Dhooge I; Dhooge C; Geukens S; De Clerck B; De Vel E; Vinck BM
Int J Audiol; 2006 Jun; 45(6):337-43. PubMed ID: 16777780
[TBL] [Abstract][Full Text] [Related]
9. [Effects of Cisplatin on Auditory Function in Children with cancer. Otoacoustic Emission Evaluation].
Toral-Martiñón R; Poblano A; Collado-Corona MA; González R
Gac Med Mex; 2003; 139(6):529-34. PubMed ID: 14723047
[TBL] [Abstract][Full Text] [Related]
10. Monitoring of cisplatin ototoxicity by distortion-product otoacoustic emissions.
Ozturan O; Jerger J; Lew H; Lynch GR
Auris Nasus Larynx; 1996; 23():147-51. PubMed ID: 8809338
[TBL] [Abstract][Full Text] [Related]
11. Detection of cisplatin-induced ototoxicity with transient evoked otoacoustic emission test before pure tone audiometer.
Yilmaz S; Oktem F; Karaman E
Eur Arch Otorhinolaryngol; 2010 Jul; 267(7):1041-4. PubMed ID: 19946777
[TBL] [Abstract][Full Text] [Related]
12. Time-frequency analysis of transient-evoked otoacoustic emissions in children exposed to carboplatin chemotherapy.
Bhagat S; Bass J; Qaddoumi I; Brennan R; Wilson M; Wu J; Galindo CR; Paglialonga A; Tognola G
Audiol Neurootol; 2013; 18(2):71-82. PubMed ID: 23147804
[TBL] [Abstract][Full Text] [Related]
13. Changes of stapedius reflex and hearing threshold in patients receiving high-dose cisplatin treatment.
Laurell G; Skedinger M
Audiology; 1990; 29(5):252-61. PubMed ID: 2275640
[TBL] [Abstract][Full Text] [Related]
14. [Hearing loss caused by high dose carboplatin therapy].
Lautermann J; Adamczyk M; ten Cate WJ; Kloke O
Laryngorhinootologie; 1998 Feb; 77(2):82-4. PubMed ID: 9555700
[TBL] [Abstract][Full Text] [Related]
15. Otoacoustic emissions and the categorization of cochlear and retro-cochlear lesions.
Patuzzi R
Br J Audiol; 1993 Apr; 27(2):91-5. PubMed ID: 8220287
[TBL] [Abstract][Full Text] [Related]
16. Effect of protective agents against cisplatin ototoxicity.
Rybak LP; Husain K; Morris C; Whitworth C; Somani S
Am J Otol; 2000 Jul; 21(4):513-20. PubMed ID: 10912697
[TBL] [Abstract][Full Text] [Related]
17. Effects of acoustic stimuli used for vestibular evoked myogenic potential studies on the cochlear function.
Krause E; Mayerhofer A; Gürkov R; Drexl M; Braun T; Olzowy B; Boetzel K
Otol Neurotol; 2013 Sep; 34(7):1186-92. PubMed ID: 23921920
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
19. Carboplatin is ototoxic.
Kennedy IC; Fitzharris BM; Colls BM; Atkinson CH
Cancer Chemother Pharmacol; 1990; 26(3):232-4. PubMed ID: 2192812
[TBL] [Abstract][Full Text] [Related]
20. Otoacoustic emissions--an approach for monitoring aminoglycoside induced ototoxicity in children.
Stavroulaki P; Apostolopoulos N; Dinopoulou D; Vossinakis I; Tsakanikos M; Douniadakis D
Int J Pediatr Otorhinolaryngol; 1999 Nov; 50(3):177-84. PubMed ID: 10595663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
